American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 366-370 , September 2007

Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Dialysis Provider’s Perspective

  • J. Michael Lazarus, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to J. Michael Lazarus, MD, or Raymond M. Hakim, MD, PhD, Fresenius Medical Care North America, 920 Winter St, Lexington, MA 02451.
    • ,
  • Raymond M. Hakim, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress correspondence to J. Michael Lazarus, MD, or Raymond M. Hakim, MD, PhD, Fresenius Medical Care North America, 920 Winter St, Lexington, MA 02451.

References 

  1. Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernán MA. Dialysis facility ownership and epoetin dose in patients receiving hemodialysis. JAMA. 2007;297:1667–1674
  2. Coyne DW. Use of epoetin in chronic renal failure. JAMA. 2007;297:1713–1716
  3. US Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. In: Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007;p. 191–204
  4. Drüeke TB, Locatelli F, Clyne N, et al. CREATE Investigators Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  5. Singh AK, Szczech L, Tang KL, et al. CHOIR Investigators Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  6. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  7. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58:1325–1335
  8. Furuland H, Linde T, Ahlmén J, Christensson A, Strömbom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant. 2003;18:353–361
  9. Collins AJ, Brenner RM, Ofman JJ, et al. Epoetin alfa use in patients with ESRD: An analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis. 2005;46:481–488
  10. Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int. 2004;65:626–633
  11. Collins AJ, Li S, St. Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001;12:2465–2473
  12. Ofsthun N, LaBrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hematocrit levels on mortality and hospitalization in hemodialysis patients. Kidney Int. 2003;63:1908–1914
  13. Avram MM, Blaustein D, Fein PA, Goel N, Chattopadhyay J, Mittman N. Hemoglobin predicts long-term survival in dialysis patients: A 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney Int Suppl. 2003;87:S6–S11
  14. Lacson E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003;41:111–124
  15. Children’s Health and Medicare Protection Act of 2007, 3162 HR §637, 2007

PII: S0272-6386(07)01037-2

doi: 10.1053/j.ajkd.2007.07.008

American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 366-370 , September 2007

Article Tools

* Image Usage & Resolution